Skip to content
value.today

180 Life Sciences Corp.

🇺🇸 Menlo Park, California, USAPharmaceuticalsFounded 2016

Formerly KBL Merger Corp. IV

180 Life Sciences Corp. is listed today as Forum Markets, Incorporated: market value, financials and filings are on its company page.

Funding rounds

0 counted as startup funding, 4 other private sales on record. Open the number of investors for the round's details.

Funding rounds of 180 Life Sciences Corp.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2025$425 MPrivate placement after listing$250 million to $1 billion

180 Life Sciences Corp.: Private sale, Jul 2025

Investors in this round

80 investors had bought by the notice of Sep 15, 2025: 80 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for 180 Life Sciences Corp. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$425 M of $425 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$34,153,881
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Eric Van Lent · Executive Officer
  • McAndrew Rudisill · Executive Officer, Director
  • Andrew H. Suckling · Director
  • Crystal H. Heter · Director
  • Ryan Smith · Director
  • Stephen H. Shoemaker · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Clear Street LLC (CRD 000288933) · New York, New YorkSold in all US states

Remarks in the notice

  • On fees: “Estimate includes 2% cash fee and 2% equity fee on shares issued in PIPE.”

Signed by McAndrew Rudisill, Chief Executive Officer. Source: SEC Form D, newest notice filed Sep 15, 2025. Read the notice at the SEC.

equity, optionsSEC
Dec 2024$3 MPrivate placement after listing$2 to $10 million

180 Life Sciences Corp.: Private sale, Dec 2024

Investors in this round

5 investors had bought by the notice of Jan 10, 2025: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for 180 Life Sciences Corp. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$223,169
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Blair Jordan · Executive Officer, Director
  • Jay Goodman · Director
  • Lawrence Steinman · Director
  • Ryan Smith · Director
  • Stephen Shoemaker · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Maxim Group LLC (CRD 000120708) · New York, New YorkSold in CA, CT, FL, NJ, NV, NY, and outside the US
  • A.G.P./Alliance Global Partners (CRD 000008361) · New York, New YorkSold in NY, and outside the US

Remarks in the notice

  • On the amounts: “Represents total gross proceeds received by the company in connection with a registered direct offering of shares of common stock and a concurrent private placement of common stock purchase warrants.”

Signed by Blair Jordan, Interim Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 10, 2025. Read the notice at the SEC.

equity, optionsSEC
Aug 2021$15 MPrivate placement after listing$10 to $50 million

180 Life Sciences Corp.: Private sale, Aug 2021

Investors in this round

12 investors had bought by the notice of Sep 1, 2021: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for 180 Life Sciences Corp. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$15 M of $15 M offered
Smallest investment taken
$189,498
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,050,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • James N. Woody · Executive Officer, Director
  • Ozan N. Pamir · Executive Officer
  • Donald A. McGovern · Director
  • Francis A. Knuettel · Director
  • Larry N. Gold · Director
  • Lawrence N. Steinman · Director
  • Marc N. Feldmann · Director
  • Pamela A. Marrone · Director
  • Russel T. Ray · Director
  • Teresa A. DeLuca · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Maxim Group LLC (CRD 120708) · New York, New YorkSold in CT, IL, NY, and outside the US

Signed by James N. Woody, M.D., Ph.D., Chief Executive Officer. Source: SEC Form D, newest notice filed Sep 1, 2021. Read the notice at the SEC.

equity, optionsSEC
Feb 2021$12 MPrivate placement after listing$10 to $50 million

180 Life Sciences Corp.: Private sale, Feb 2021

Investors in this round

11 investors had bought by the notice of Feb 26, 2021: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for 180 Life Sciences Corp. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$12 M of $12 M offered
Smallest investment taken
$555,100
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$816,634
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • James N. Woody · Executive Officer, Director
  • Ozan N. Pamir · Executive Officer
  • Donald A. McGovern · Director
  • Larry N. Gold · Director
  • Lawrence N. Steinman · Director
  • Marc N. Feldmann · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Maxim Group LLC (CRD 120708) · New York, New YorkSold in IL, NY, and outside the US

Signed by James N. Woody, M.D., Ph.D., Chief Executive Officer. Source: SEC Form D, newest notice filed Feb 26, 2021. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Forum Markets, Incorporated, its revenue in fiscal 2025 came from these product and service lines: Liquid staking revenue $5.95 million (91%), Native staking revenue $460,000 (7%), Reward revenue $140,000 (2%).

    Annual report (SEC XBRL) · Dec 2025

  • 180 Life Sciences Corp. chose not to state its revenue in its newest notice of a funding round (Sep 2025).

    SEC Form D · Sep 2025

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Sep 2025

Products and services#

No products or services of 180 Life Sciences Corp. are on record.

Investors#

1 named in official filings. Open an investor to see everything it has backed.

Investors in 180 Life Sciences Corp.
InvestorKindAmountRoundRoleSource
Elray Resources, Inc.Companynot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2024)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete.

Largest shareholders today

Institutions holding Forum Markets, Incorporated shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by 180 Life Sciences Corp.
NameRoleNamed in
Eric Van LentExecutive officerSep 2025
McAndrew RudisillExecutive officerSep 2025
Blair JordanExecutive officerJan 2025
James N. WoodyExecutive officerSep 2021
Ozan N. PamirExecutive officerSep 2021
Andrew H. SucklingDirectorSep 2025
Crystal H. HeterDirectorSep 2025
McAndrew RudisillDirectorSep 2025
Ryan SmithDirectorSep 2025
Stephen H. ShoemakerDirectorSep 2025
Blair JordanDirectorJan 2025
Jay GoodmanDirectorJan 2025
Lawrence SteinmanDirectorJan 2025
Stephen ShoemakerDirectorJan 2025
Donald A. McGovernDirectorSep 2021
Francis A. KnuettelDirectorSep 2021
James N. WoodyDirectorSep 2021
Larry N. GoldDirectorSep 2021
Lawrence N. SteinmanDirectorSep 2021
Marc N. FeldmannDirectorSep 2021
Pamela A. MarroneDirectorSep 2021
Russel T. RayDirectorSep 2021
Teresa A. DeLucaDirectorSep 2021

Went public since 2019. Its SEC number is that of a company listed on a stock exchange.